THis study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab or Atezolizumab combined with Bevacizumab for the first-line treatment of advanced HCC.
Able and willing to provide a written informed consent.
≥ 18 years old, both male and female.
Unresectable locally advanced or metastatic HCC confirmed by histopathologically/cytologically.
At least one measurable lesion based on RECIST v1.1 criteria.
Hepatic cholangiocarcinoma, mixed hepatocellular carcinoma -cholangiocarcinoma, sarcomatoid hepatocellular carcinoma and fibrolamellar hepatocellular carcinoma.
Patients with other malignancies currently or within the past 5 years.
With known severe allergic reactions to any other monoclonal antibodies.
Patients with known CNS metastasis or hepatic encephalopathy.